Last reviewed · How we verify
BAY2927088 coated tablet 10 mg
BAY2927088 coated tablet 10 mg is a Small molecule drug developed by Bayer. It is currently in Phase 1 development.
At a glance
| Generic name | BAY2927088 coated tablet 10 mg |
|---|---|
| Sponsor | Bayer |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study Evaluating How Moderate Liver Impairment Affects the Absorption, Distribution, Metabolism, and Elimination of Sevabertinib After a Single Oral Dose (PHASE1)
- A Study to Learn How BAY2927088 is Taken up and Handled by the Body in Healthy Male Participants (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BAY2927088 coated tablet 10 mg CI brief — competitive landscape report
- BAY2927088 coated tablet 10 mg updates RSS · CI watch RSS
- Bayer portfolio CI
Frequently asked questions about BAY2927088 coated tablet 10 mg
What is BAY2927088 coated tablet 10 mg?
BAY2927088 coated tablet 10 mg is a Small molecule drug developed by Bayer.
Who makes BAY2927088 coated tablet 10 mg?
BAY2927088 coated tablet 10 mg is developed by Bayer (see full Bayer pipeline at /company/bayer).
What development phase is BAY2927088 coated tablet 10 mg in?
BAY2927088 coated tablet 10 mg is in Phase 1.
Related
- Manufacturer: Bayer — full pipeline
- Compare: BAY2927088 coated tablet 10 mg vs similar drugs
- Pricing: BAY2927088 coated tablet 10 mg cost, discount & access